Continuous intravenous pumping (CIP) of recombinant human endostatin (Endostar) combined with concurrent radiochemotherapy in patients with unresectable stage Ⅲ non-small-cell lung cancer:preliminary data of a prospective multicenter phaseⅡclinical trial
Department of Radiation Oncology,Zhejiang Cancer Hospital,Key Laboratory of Radiation Oncology in Zhejiang Province,Hangzhou 310022,China (Ma HL,Xu YJ,Kong Y,Chen M);Department of Radiation Oncology,Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College,Beijing 10021,China (Hui ZHG,Zhai YR,Wu RY,Tang Y,Liang J,Wang LH);Department of Radiation Oncology,Tianjin Medical University Cancer Hospital,Tianjin 300060,China (Zhao LJ,Pang QS);Department of Radiation Oncology,Peking University School of Oncology,Beijing Cancer Hospital,Beijing 100142,China (Li DM,Zhu GY)
Abstract：Objective Preclinical models have shown that recombinant human endostatin (Endostar) can transiently normalize the tumor vasculature to make it more efficient for oxygen delivery,which provides a treatment window of enhancing tumor radiosensitivity. This study is to evaluate the safety and efficacy of continuous intravenous pumping (CIP) of Endostar combined with standard concurrent radiochemotherapy for unresectable stage III non-small-cell lung cancer (NSCLC). Methods In this prospective study,patients with unresectable stage IIIA or IIIB NSCLC received CIP of Endostar (7.5 mg/m2) over 5 days at week 1,3,5,and 7.During week 2-8,patients received two 28-day cycles of etoposide 50 mg/m2 on day 1-5 and cisplatin 50 mg/m2 on day 1,8,with concurrent thoracic radiation of 60-66 Gy in 30-33 fractions over 6-7 weeks. Acute toxicities were evaluated using CTCAE 3.0.Tumor response was evaluated using RECIST 1.1 criteria. Results Between Nov.2012 and Jun.2015,63 patients were eligible for toxicity and efficacy evaluation,including 52(83%) male and 11(16%) female,41(65%) with squamous cell carcinoma,19(30%) with adenocarcinoma,1(2%) with large cell carcinoma and 2(3%) with undifferentiated carcinoma,and 27(43%) with stageIIIA disease and 36(57%) with IIIB disease,respectively. The median age was 59(31-69) years. All patients completed the treatment as planned,except that 2 patient missed one cycle chemotherapy for unrecovered grade 2 renal function impairmentandgrade Ⅳ myelosuppression. There were 8(13%),40(64%),11(18%) and 4(6%) patients achieved complete response,partial response,stable disease and progressive disease,respectively. The objective remission rate (ORR) is 76%.There were 23 patients (37%) with grade 3+4 neutropenia,9(14%) with grade 3+4 anemia,and 10(16%) with grade 3+4 thrombocytopenic. Two patients (5%) developed grade 3 nausea/vomiting. Grade 3 acute esophagitis,grade 1+2 and grade 3 pneumonitis were observed in 8(13%),12(19%) and 2(3%) patients,respectively. No grade 2 cardiovascular toxicity was observed.Up to the last follow-up,the median follow-up time was 13.6 months.21 deaths were observed,including 15 died of cancer progression. The median PFS was 14.8 months. The 1-year PFS,OS was 51%,78%,respectively. Conclusions For patients with unresectable stageIII NSCLC,CIP of Endostar enhanced patient compliance,and combined with concurrent radiochemotherapy is tolerable and the short term outcomes are promising. Long term survival data await further follow up.Clinical Trial Registry ClinicalTrials.gov,registration number:NCT01733589.
. Continuous intravenous pumping (CIP) of recombinant human endostatin (Endostar) combined with concurrent radiochemotherapy in patients with unresectable stage Ⅲ non-small-cell lung cancer:preliminary data of a prospective multicenter phaseⅡclinical trial[J]. Chinese Journal of Radiation Oncology, 2016, 25(2): 114-118.
[1]Curran WJ Jr,Paulus R,Langer CJ,et al. Sequential vs.concurrent chemoradiation for stage Ⅲ non-small cell lung cancer:randomized phase Ⅲ trial RTOG 9410[J].J Natl Cancer Inst,2011,103(19):1452-1460.DOI:10.1093/jnci/djr325. [2]Rengan R,Maity AM,Stevenson JP,et al. New strategies in non-small cell lung cancer:improving outcomes in chemoradiotherapy for locally advanced disease[J].Clin Cancer Res,2011,17(13):4192-4199.DOI:10.1158/1078-0432.CCR-10-2760. [3]Furuse K,Fukuoka M,Kawahara M,et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin,vindesine,and cisplatin in unresectable stage Ⅲ non-small-cell lung cancer[J].J Clin Oncol,1999,17(9):2692-2699. [4]Jeremic B,Shibamoto Y,Acimovic L,et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage Ⅲ non-small-cell lung cancer:a randomized study[J].J Clin Oncol,1996,14(4):1065-1070. [5]Schaake-Koning C,van den Bogaert W,Dalesio O,et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer[J].N Engl J Med,1992,326(8):524-530.DOI:10.1056/NEJM199202203260805. [6]Zatloukal P,Petruzelka L,Zemanova M,et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer:a randomized study[J].Lung Cancer,2004,46(1):87-98.DOI:10.1016/j.lungcan.2004.03.004. [7]Belani CP,Lee JS,Socinski MA,et al. Randomized phase Ⅲ trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer[J].Ann Oncol,2005,16(7):1069-1075.DOI:10.1093/annonc/mdi216. [8]Oh IJ,Kim KS,Kim YC,et al. A phase Ⅲ concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer:KASLC 0401[J].Cancer Chemother Pharmacol,2013,72(6):1247-1254.DOI:10.1007/s00280-013-2308-5. [9]Liew MS,Sia J,Starmans MHW,et al. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage Ⅲ non-small cell lung cancer[J].Cancer Med,2013,2(6):916-924.DOI:10.1002/cam4.142. [10]Bradley JD,Paulus R,Komaki R,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage ⅢA or ⅢB non-small-cell lung cancer (RTOG 0617):a randomised,two-by-two factorial phase 3 study[J].Lancet Oncol,2015,16(2):187-199.DOI:10.1016/S1470-2045(14)71207-0. [11]Winkler F,Kozin SV,Tong RT,et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation:role of oxygenation,angiopoietin-1,and matrix metalloproteinases[J].Cancer Cell,2004,6(6):553-563.DOI:10.1016/j.ccr.2004.10.011. [12]Soria JC,Mauguen A,Reck M,et al. Systematic review and meta-analysis of randomised,phase Ⅱ/Ⅲ trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer[J].Ann Oncol,2013,24(1):20-30.DOI:10.1093/annonc/mds590. [13]Yang ZY,Liu L,Mao C,et al. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer[J].Cochrane Database Syst Rev,2014,11:CD009948.DOI:10.1002/14651858.CD009948. [14]Nieder C,Pawinski A,Dalhaug A,et al. A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer[J].Radiat Oncol,2012,7:3.DOI:10.1186/1748-717X-7-3. [15]Jain RK.Normalizing tumor microenvironment to treat cancer:bench to bedside to biomarkers[J].J Clin Oncol,2013,31(17):2205-2218.DOI:10.1200/JCO.2012.46.3653. [16]Jain RK.Antiangiogenesis strategies revisited:from starving tumors to alleviating hypoxia[J].Cancer Cell,2014,26(5):605-622.DOI:10.1016/j.ccell.2014.10.006. [17]Jiang XD,Dai P,Qiao Y,et al. Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer[J].Clin Transl Oncol,2012,14(6):437-443.DOI:10.1007/s12094-012-0821-3. [18]Jiang XD,Dai P,Wu J,et al. Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2012,83(4):1272-1277.DOI:10.1016/j.ijrobp.2011.09.050. [19]Jiang XD,Qiao Y,Dai P,et al. Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC[J].Clin Transl Oncol,2012,14(6):465-470.DOI:10.1007/s12094-012-0825-z. [20]Meng MB,Jiang XD,Deng L,et al. Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling:experimental and clinical evidence[J].Radiother Oncol,2013,106(1):130-137.DOI:10.1016/j.radonc.2012.10.022. [21]Peng F,Xu ZM,Wang J,et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models[J].PLoS One,2012,7(4):e34646.DOI:10.1371/journal.pone.0034646. [22]彭芳,王谨,邹毅,等.重组内皮抑素对肿瘤血管结构和乏氧改善作用的实验观察[J].中华放射肿瘤学杂志,2011,20(1):69-72.DOI:10.3760/cma.j.issn.1004-4221.2011.01.022. Peng F,Wang J,Zou Y,et al. Recombinant human endostatin improves tumor vasculature and alleviates hypoxia in Lewis lung carcinoma[J].Chin J Radiat Oncol,2011,20(1):69-72.DOI:10.3760/cma.j.issn.1004-4221.2011.01.022. [23]Bao Y,Peng F,Zhou QC,et al. Phase Ⅱ trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage Ⅲ non-small-cell lung cancer[J].Radiother Oncol,2015,114(2):161-166.DOI:10.1016/j.radonc.2014.11.039. [24]周琦超,包勇,余忠华,等.不可手术切除Ⅲ期非小细胞肺癌恩度联合同期放化疗多中心Ⅰ+Ⅱ期临床试验[J].中华放射肿瘤学杂志,2012,21(6):500-503.DOI:10.3760/cma.j.issn.1004-4221.2012.06.005. Zhou QC,Bao Y,Yu ZH,et al. A prospective phase Ⅰ/Ⅱstudy of recombinant endostatin (Endostar) combined with concurrent radio-chemotherapy in patients with unresectable stage Ⅲ non-small cell lung cancer[J].Chin J Radiat Oncol,2012,21(6):500-503.DOI:10.3760/cma.j.issn.1004-4221.2012.06.005. [25]Sandler A,Gray R,Perry MC,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med,2006,355(24):2542-2550.DOI:10.1056/NEJMoa061884. [26]王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. Wang JW,Sun Y,Liu YY,et al. Results of randomized,multicenter,double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients[J].Chin J Lung Cancer,2005,8(4):283-290. [27]Johnson DH,Fehrenbacher L,Novotny WF,et al. Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol,2004,22(11):2184-2191.DOI:10.1200/JCO.2004.11.022. [28]O′Reilly MS,Boehm T,Shing Y,et al. Endostatin:an endogenous inhibitor of angiogenesis and tumor growth[J].Cell,1997,88(2):277-285.DOI:10.1016/S0092-8674(00)81848-6. [29]Dhanabal M,Ramchandran R,Waterman MJF,et al. Endostatin induces endothelial cell apoptosis[J].J Biol Chem,1999,274(17):11721-11726.DOI:10.1074/jbc.274.17.11721. [30]Lind JSW,Senan S,Smit EF.Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage Ⅲ non-small-cell lung cancer[J].J Clin Oncol,2012,30(8):e104-e108.DOI:10.1200/JCO.2011.38.4552. [31]Park YH,Kim JS.Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer[J].Radiat Oncol J,2013,31(1):34-40.DOI:10.3857/roj.2013.31.1.34. [32]Zhang K,Yang SH,Zhu Y,et al. Protection against acute radiation-induced lung injury:a novel role for the anti-angiogenic agent Endostar[J].Mol Med Rep,2012,6(2):309-315.DOI:10.3892/mmr.2012.903.
2016, Vol. 25 
